Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Compulsory Licensing And Compounded Orkambi: Solutions For Excessive Prices In The Netherlands?

Executive Summary

Compulsory licensing, new R&D models, and pharmaceutical compounding are among measures that could help secure lower drugs prices, according to a report from the Dutch Council for Public Health and Society.

You may also be interested in...



US Slams Dutch IP Policy

The US embassy in the Netherlands has attacked Dutch policies on compulsory licensing and compounding. Critics have accused it of scaremongering.

US Embassy Slams Dutch Compounding Policy

The US embassy in the Netherlands has attacked Dutch policies on compounding and compulsory licensing. Critics have accused it of scaremongering.

Dutch Move On Pharmacy Compounding Could Deter Orphan Drug Launches

Medicines prepared in pharmacies are now exempt from patent law in the Netherlands, giving pharmacists greater scope to prepare their own versions of patented medicines.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS122055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel